Stockscreener 앱 받기
38.87
3.47%
-1.37
전일 마감가:
$40.24
열려 있는:
$40.07
하루 거래량:
171.52K
Relative Volume:
0.55
시가총액:
$1.97B
수익:
$357.71M
순이익/손실:
$-20.10M
주가수익비율:
-93.98
EPS:
-0.4136
순현금흐름:
$28.67M
1주 성능:
-1.66%
1개월 성능:
+26.11%
6개월 성능:
+2.16%
1년 성능:
+25.42%
1일 변동 폭
$38.51
$40.71
1주일 범위
$35.80
$40.71
52주 변동 폭
$23.15
$40.71
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
IMCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
38.95 | 2.03B | 357.71M | -20.10M | 28.67M | -0.4136 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.27 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.81 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.71 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
902.23 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.61 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | Wells Fargo | Overweight |
| 2025-09-18 | 재개 | Guggenheim | Neutral |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2025-05-27 | 개시 | Deutsche Bank | Buy |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-10-24 | 개시 | UBS | Sell |
| 2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 개시 | Robert W. Baird | Outperform |
| 2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 개시 | Needham | Buy |
| 2023-08-16 | 개시 | CapitalOne | Overweight |
| 2023-07-17 | 개시 | Canaccord Genuity | Hold |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-03-30 | 개시 | Guggenheim | Buy |
| 2023-03-24 | 개시 | Bryan Garnier | Buy |
| 2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-30 | 개시 | Barclays | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
| 2022-08-08 | 개시 | Cowen | Outperform |
| 2022-08-02 | 개시 | BTIG Research | Buy |
| 2022-02-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-20 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | Goldman | Neutral |
| 2021-03-02 | 개시 | JP Morgan | Overweight |
| 2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Immunocore stock hits 52-week high at 40.71 USD - Investing.com
Immunocore stock hits 52-week high at 40.71 USD By Investing.com - Investing.com South Africa
Immunocore (NASDAQ:IMCR) Shares Gap DownHere's What Happened - MarketBeat
Immunocore Holdings stock hits 52-week high at $40.53 - Investing.com
Immunocore Holdings stock hits 52-week high at $40.53 By Investing.com - Investing.com South Africa
Immunocore announces board and executive departures with no reported disagreements - Investing.com
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Immunocore stock hits 52-week high at 39.5 USD - Investing.com
Immunocore at Jefferies Conference: Strategic Expansion and Innovation By Investing.com - Investing.com South Africa
Immunocore at Jefferies Conference: Strategic Expansion and Innovation - Investing.com
A Fresh Look at Immunocore Holdings (NasdaqGS:IMCR) Valuation After Positive Phase 1 Data for HBV Therapy - Sahm
Immunocore Holdings (IMCR) Is Up 7.3% After Promising Early Hepatitis B Immunotherapy Results and Revenue Gains - Sahm
Acadian Asset Management LLC Acquires 72,355 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - Defense World
Positive Hepatitis B Trial Data Might Change the Case for Investing in Immunocore Holdings (IMCR) - Sahm
Immunocore reports promising data for HBV treatment candidate By Investing.com - Investing.com South Africa
Immunocore reports promising data for HBV treatment candidate - Investing.com
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting - GlobeNewswire Inc.
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $60.89 - Defense World
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? - sharewise.com
State of New Jersey Common Pension Fund D Purchases New Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Y Intercept Hong Kong Ltd Makes New $1.62 Million Investment in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immunocore (NASDAQ:IMCR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
H.C. Wainwright reaffirms Buy rating on Immunocore stock at $100 target - Investing.com
TD Asset Management Inc Sells 9,590 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Stocks Showing Improved Relative Strength: Immunocore Holdings ADR - Investor's Business Daily
Goldman Sachs Group Inc. Sells 4,782 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR - Defense World
Embracer Group AB (publ) (LON:0GFE) Shares Up 3% – Here’s Why - Defense World
Immunocore (NASDAQ:IMCR) Insider Sells $803,716.44 in Stock - MarketBeat
Immunocore (NASDAQ:IMCR) Now Covered by Analysts at Guggenheim - Defense World
Vericel (NASDAQ:VCEL) Shares Gap Down on Analyst Downgrade - Defense World
Monument Circle Acquisition (OTCMKTS:MONCU) Shares Down 0.3% – What’s Next? - Defense World
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.89 Average Price Target from Analysts - MarketBeat
H.C. Wainwright reaffirms Buy rating on Immunocore stock, maintains $100 target - Investing.com
Green Energy Stocks Worth Watching – September 12th - Defense World
Cubist Systematic Strategies LLC Reduces Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Hold” by Analysts - Defense World
Banque Transatlantique SA Acquires Shares of 10,150 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Baker BROS. Advisors LP Has $68.91 Million Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Stellar AfricaGold (CVE:SPX) Shares Up 25.8% – What’s Next? - Defense World
Frazier Life Sciences Management L.P. Has $8.94 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects - Investing.com India
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects By Investing.com - Investing.com South Africa
Immunocore Holdings plc ADR (NASDAQ: IMCR) Rises 9.33% In Recent Trading, What’s Next? - stocksregister.com
Emergent Biosolutions Inc. $EBS Holdings Trimmed by Invesco Ltd. - Defense World
Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이뮤노코어 홀딩스 주식 (IMCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Option Exercise |
17.46 |
5,521 |
96,397 |
5,521 |
| Berman David M | HEAD OF R&D |
Nov 26 '25 |
Sale |
40.12 |
69,404 |
2,784,488 |
0 |
| Berman David M | HEAD OF R&D |
Nov 28 '25 |
Sale |
40.09 |
5,521 |
221,337 |
0 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Option Exercise |
17.46 |
18,020 |
314,629 |
18,020 |
| Berman David M | HEAD OF R&D |
Nov 24 '25 |
Option Exercise |
17.46 |
100 |
1,746 |
100 |
| Berman David M | HEAD OF R&D |
Nov 25 '25 |
Sale |
40.03 |
18,020 |
721,341 |
0 |
| Berman David M | HEAD OF R&D |
Nov 24 '25 |
Sale |
40.00 |
100 |
4,000 |
0 |
0.77%
0.84%
자본화:
|
볼륨(24시간):